Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Google Secures Pentagon AI Deal for Classified Projects 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
NEW YORK, Feb. 18, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 25, 2016, to discuss financial results for the fourth quarter and year ended December, 31, 2015, and provide a business update.
To access the live conference call via phone, dial 1-844-835-6563. The International dial-in number is 1-970-315-3916. The conference ID number for the live call is 45850524.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
CONTACT: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
